← Leaderboards
McDonald K Horne
Clinical Center
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Clinical Center
Same institution · by research overlap
Others in their field
Top investigators on “Fibrinolysis”
- Katherine M Detre · University Of Pittsburgh At Pittsburgh$33,288,043
- Sheryl F. Kelsey · University Of Pittsburgh At Pittsburgh$22,065,571
- Guy L Reed · Harvard University (Sch Of Public Hlth)$12,951,913
- Walter N Kernan · Yale University$11,636,848
- Edward Franklin Plow · Cleveland Clinic Foundation$10,498,878
- Mortimer Poncz · University Of Pennsylvania$10,342,221
Research focus
FibrinolysisHuman SubjectClinical ResearchHuman TissueHeparinPlasminogen ActivatorInjection /InfusionPlasminogen Activator InhibitorsPlateletsPatient Oriented ResearchThrombinBlood Coagulation DisordersBlood CoagulationCoagulation Factor ViiiPlasminogenHemorrhageCrosslinkMonoclonal AntibodyInsulin Sensitivity /ResistanceAnticoagulantsMembrane ProteinsBinding SitesFibrinAntithrombins
Grant awards (37)
A Comparison of Fibrinolysis of Clots from Venipuncture and Fingerstick Blood$39,000
Z01 · FY2007 · CL · contact PI
A Whole Blood Thrombin Generation Assay to Assess Hypercoagulability$14,000
Z01 · FY2007 · CL · contact PI
Treament of Deep Vein Thrombosis of the Lower Extremities w/Low Dose Alteplase$5,000
Z01 · FY2007 · CL · contact PI
A Comparison of Fibrinolysis of Clots from Venipuncture$0
Z01 · FY2006 · CL · contact PI
A Whole Blood Thrombin Generation Assay to Assess Hyperc$0
Z01 · FY2006 · CL · contact PI
Treament of Deep Vein Thrombosis of the Lower Extremitie$0
Z01 · FY2006 · CL · contact PI
Heparin vs Lepirudin in Preventing Withdrawal Occulusion$0
Z01 · FY2005 · CL
Interaction Of Plasminogen With Human Platelets$0
Z01 · FY2005 · CL
Evaluation Of Hypercoagulability In Patients w/ MD$0
Z01 · FY2005 · CL
A Comparison of Fibrinolysis of Clots from Venipuncture$0
Z01 · FY2005 · CL
A Whole Blood Thrombin Generation Assay to Assess Hyperc$0
Z01 · FY2005 · CL
Treament of Deep Vein Thrombosis of the Lower Extremitie$0
Z01 · FY2005 · CL
An Analysis of Laboratory Tests for Thrombocytopenia$0
Z01 · FY2005 · CL
The Effect of Thyroid Hormone on Hypercoagulability$0
Z01 · FY2005 · CL
Adsorption of Lepirudin to Silicone$0
Z01 · FY2004 · CL
Interaction Of Plasminogen With Human Platelets$0
Z01 · FY2004 · CL
Evaluation Of Hypercoagulability In Patients With Major$0
Z01 · FY2004 · CL
Heparin vs. Lepirudin in Preventing Withdrawal Occulusio$0
Z01 · FY2004 · CL
Effect of Thyroid Hormone on Parameters of Hypercoagulab$0
Z01 · FY2004 · CL
Pharmacokinetics of Pulse-Sprayed TPA$0
Z01 · FY2004 · CL
Analysis of Lab Tests for Heparin-Induced Thrombocytopen$0
Z01 · FY2004 · CL
Treament of Deep Vein Thrombosis with Alteplase$0
Z01 · FY2004 · CL
Interaction Of Plasminogen With Human Platelets$0
Z01 · FY2003 · CL
Lab Tests for Heparin Induced Thrombocytopenia$0
Z01 · FY2003 · CL
Pharmacokinetics of Pulse-Sprayed TPA$0
Z01 · FY2003 · CL
Thyroid Hormone Effects on Hypercoagulability$0
Z01 · FY2003 · CL
Adsorption of Lepirudin to Silicone$0
Z01 · FY2003 · CL
Heparin /Lepirudin in Occlusion Of Venus Access Device$0
Z01 · FY2003 · CL
Evaluation Of Hypercoagulability In Patients With Major$0
Z01 · FY2003 · CL
Interaction Of Plasminogen With Human Platelets$0
Z01 · FY2002 · CL
Hypercoagulability In Patients With Major Depression$0
Z01 · FY2002 · CL
Coagulant And Fibrinolytic Parameters In Postmenopausal$0
Z01 · FY2002 · CL
Histidine-rich Glycoprotein: Characterization And Clinic$0
Z01 · FY2002 · CL
Characterization of Histidine-rich Glycoprotein$0
Z01 · FY2001 · CL
Interaction Of Plasminogen With Human Platelets$0
Z01 · FY2001 · CL
Biochemical Parameters of Coagulation and Fibrinolysis in Postmenopausal Women W$0
Z01 · FY2000 · CL
Histidine-Rich Glycoprotein: Characterization and Clinical Significance Studies$0
Z01 · FY2000 · CL